EGFR and colorectal cancer: Recently, two studies of plasma DNA sequencing in colorectal cancer patients undergoing treatment with EGFR monoclonal antibodies jointly identified the first MAP2K1 codon K57 resistance mutations (p.K57T and p.K57N) (Russo et al. 2015; Siravegna et al. 2015).